© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
April 15, 2021
Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy.
Ryan Haumschild, PharmD, MS, MBA, provides insight on biosimilar adoption both in oncology and non-oncology practice settings.
Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.
April 13, 2021
As the FDA and CDC have paused use of the Johnson & Johnson COVID-19 vaccine in the United States, research is ongoing to understand whether cerebral venous sinus thrombosis (CVST) is directly linked to the vaccine.
The impact on biosimilar utilization in clinical practice caused by secondary patents of biologics and skinny labels of biosimilars is discussed.
April 12, 2021
Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.
April 09, 2021
Madeline Camejo, PharmD, and Estela Trimino, PharmD, BCPS, discuss the emerging role of the pharmacist on the front line of vaccine administration.
Health system pharmacists discuss challenges with the COVID-19 vaccine rollout, such as having multiple vaccine types and lot numbers on hand and appointment no-shows
Megan May, PharmD, BCOP, Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, share their thoughts on unmet needs in the management of neuroendocrine tumors.
The experts discuss measures taken by pharmacy to prevent waste of vaccine doses and the education provided to members of the medical staff.